Clinical Trial

A Single-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247) in Study Participants With HRD-negative Epithelial Ovarian Cancer

Study acronym: YS247
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, dose-escalation, multiple-dose investigator-initiated exploratory study designed to evaluate the safety, tolerability and preliminary efficacy of tumor neoantigen-pulsed autologous dendritic cell injection (YS247) in participants with HRD-negative epithelial ovarian cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-02.
Trial Details
NCT Number NCT07455071
Lead Sponsor Peking University Third Hospital
Conditions HRD-negative Epithelial Ovarian Cancer
Enrollment 9 participants
Start Date 2026-03-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-16